Skip to main content

Table 1 Characteristics of the included studies

From: Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP)

First Author & Year of Publication

Country

Study design

ICO

S/M

level of evidencea

VEGF Inhibitors

Laser

MFT(m)

SS

Rec

Ret

Com

SE(D)

TTR(w)

SS

Rec

Ret

Com

SE(D)

TTR(w)

Mintz-Hittner 2011 [13]

USA

RCT

YES

M

2b

140

6/4.3

NG

2/1.4

NG

NG

146

32/21.9

NG

6/4.1

NG

NG

8

Harder 2013 [16]

Germany

CNS

YES

S

3

23

0/0

0/0

0/0

−1.04 ± 4.24

NG

26

1/3.8

1/3.8

1/3.8

−4.41 ± 5.50

NG

12

Moran 2014 [12]

Ireland

RCT

YES

S

2b

14

3/21.4

3/21.4

NG

NG

16.00 ± 1.00

14

1/7.1

1/7.1

NG

NG

2.00 ± 0.01

24

Lepore 2014 [24]

Italy

RCT

YES

S

2b

12

0/0

0/0

0/0

NG

NG

12

1/8.3

1/8.3

1/8.3

NG

NG

9

Isaac 2015 [8]

Canada

CNS

YES

S

3

23

0/0

0/0

0/0

−3.57 ± 6.19

NG

22

1/4.5

1/4.5

0/0

−6.39 ± 4.41

NG

>9

Hwang 2015 [9]

USA

CNS

YES

S

3

22

3/13.6

NG

0/0

2.40 ± 3.50

9.00 ± 5.70

32

1/3.1

NG

6/18.8

−5.30 ± 5.40

2.60 ± 0.01

6–40

Gunay 2016 [11]

Turkey

CNS

YES

M

3

133

28/21.1

12/9.0

NG

NG

NG

111

1/0.9

0/0

NG

NG

NG

18

Karkhaneh 2016 [25]

Iran

RCT

YES

S

2b

86

9/10.5

9/10.5

0/0

NG

5.07 ± 1.66

72

1/1.4

1/1.4

0/0

NG

3 ± 0.01

22.5

Mueller 2016 [7]

Germany

CNS

YES

S

3

74

7/9.5

5/6.8

1/1.4

NG

NG

34

0/0

0/0

4/11.8

NG

NG

12

Walz 2016 [26]

Germany

CNS

YES

M

3

33

NG

5/15.1

NG

NG

NG

129

NG

18/14.0

NG

NG

NG

–

      

560

     

598

      
  1. RCT, Randomized Controlled Trial; CNS, Comparative Non-randomized Study; ICO, Informed Consent Obtained; S/M, Single−/Multi-centre; SS, Sample Size (eye number); Rec, Recurrence number/incidence(eye number/incidence); Ret, Retreatment number/incidence (eye number/incidence); Com, Complication number/incidence (eye number/incidence); SE(D), Spherical Equivalent at Last Follow-up (Dioptre); TTR(w), Time between Treatment and Retreatment (week); MFT, Mean Follow-up time (months); NG, Not Given
  2. Level of Evidencea: according to the criteria by the Center for Evidence-Based Medicine [21]